LUCIANA PARENTE COSTA SEGURO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
bookPart Osteoporose induzida por glicocorticoide(2021) PEREIRA, Rosa Maria Rodrigues; SEGURO, Luciana Parente Costa; DOMICIANO, Diogo SouzabookPart Lúpus eritematoso sistêmico(2021) BORBA NETO, Eduardo Ferreira; SEGURO, Luciana Parente Costa; LOPES, Michelle Remião Ugolini; GONçALVES, Célio Roberto; BONFá, EloisaconferenceObject Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort(2021) NIETO, Romina; BORBA, Eduardo Ferreira; SETTECASSE, Eugenia; FERNANDEZ-AVILA, Diana; MAURELLI, Laura; GOBBI, Carla; SAURIT, Veronica; ARIZPE, Fernando; DANIELE, Julieta; BERTOLACCINI, Maria Constanza; KERZBERG, Eduardo; GARGIULO, Maria de los Angeles; RODRIGUEZ, Anabella; LONDE, Ana Carolina; BARBOSA, Vitalina Sousa; GASPARIN, Andrese Aline; ANDRADE, Carolina Albanez A. Cunha; SEGURO, Luciana Parente Costa; MARTINS, Lucas Victoria de Oliveira; NEIRA, Oscar; LLANOS, Carolina; MASSARDO, Loreto; IGLESIAS, Antonio; ARISTIZABAL, Ivana Nieto; VASQUEZ, Gloria; MENDEZ-PATARROYO, Paul; RUEDA, Lizeth de la Hoz; PEREZ, Jose Martinez; BRIONES, Reyna Sanchez; CRISTOBAL, Mario Perez; MARTIN-NARES, Eduardo; JUAREZ-VICUNA, Yaneli; BELLO, Yelitza Gonzalez; GARCIA, Jorge Gonzalez; GALARZA-DELGADO, Dionicio; VAZQUEZ, Marcos; LANGJARH, Patricia; LINARES, Magaly Alva; REATEGUI-SOKOLOVA, Cristina; QUIROS, Armando Calvo; RODRIGUEZ, Edral; ROBAINA, Ricardo; REBELLA, Martin; ALARCN, Graciela; ORILLION, Ashley; KARYEKAR, Chetan; ZAZZETTI, Federico; PONS-ESTEL, Guillermo- Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy Bimodal Pattern of Onset and Treatment Response(2021) FARGETTI, Simone; UGOLINI-LOPES, Michelle R.; PASOTO, Sandra G.; SEGURO, Luciana P. C.; SHINJO, Samuel K.; BONFA, Eloisa; BORBA, Eduardo F.Background/Objective: Our aim was to describe the short- and long-term outcome of peripheral neuropathy (PN) attributed exclusively to systemic lupus erythematosus (SLE). Methods: Systemic lupus erythematosus patients with defined PN (clinical and electroneuromyography) were retrospectively evaluated at onset, 1-year, and 5-year follow-up using a standardized electronic chart database that started in 2000. Exclusion criteria were comorbidities, drugs, and infections. Age-, sex-, and disease duration-matched SLE patients without PN were selected as controls. Results: Lupus PN was identified in 38 (1.8%) of 2074 patients, and almost two thirds had PN onset in the first 5 years of SLE (63.2%). Peripheral neuropathy SLE had higher frequencies of cutaneous vasculitis (50% vs 21.1%, p = 0.002), lymphopenia (60.5% vs 36.8%, p = 0.027), anti-Sm (52.6% vs 27.6%, p = 0.013), and higher SLEDAI-2K scores (11.5 +/- 10.5 vs 4.9 +/- 6.7, p < 0.001) compared with controls. The most common type was polyneuropathy (71.1%) with sensory-motor pattern (68.4%). At PN diagnosis, all patients received glucocorticoid and 97.4% started immunosuppressive therapy (50% intravenous cyclophosphamide, 42.1% azathioprine). After 1-year follow-up, 92.1% had a favorable outcome with complete (36.8%) or partial remission (55.2%), in parallel with a decrease in prednisone dose (48.3 +/- 17.9 vs 15.3 +/- 13.4 mg/d, p < 0.001), symptomatic therapy (57.9% vs 29.7%, p = 0.02), and SLEDAI-2K score (11.5 +/- 10.5 vs 1.7 +/- 3.7, p < 0.001). SLEDAI-2K scores were higher in patientswho had PN onsetwith less than 1 year of SLE duration, compared with those with more than 5 years of disease (21.3 +/- 9.1 vs 3.9 +/- 5.3, p < 0.001). Early-PN-onset group had a better response to treatment (complete remission at 1-year follow-up 61.5% vs 25%, p = 0.039). At 5-year follow-up, 89.3% remained with complete/partial remission. Conclusions: Peripheral neuropathy attributed to SLE itself is a rare manifestation with a bimodal pattern, characterized by a predominant early-onset group associated with high disease activity and a higher rate of complete remission, and a late-onset group with low disease activity and a partial therapy response.